Jupiter Endovascular, Inc. announced that the full results of the SPIRARE II pivotal trial, evaluating the company’s Vert ...

A summary of four recent studies evaluating locoregional therapies for hepatocellular carcinoma and percutaneous ablation for ...

Gore & Associates announced FDA approval of an expanded indication for the company’s Viabahn VBX balloon expandable e ...

Penumbra, Inc. announced that the FDA has granted clearance for the treatment of deep vein thrombosis (DVT) to the company&rsqu ...

Stryker Peripheral Vascular announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) ...

A study of computer-assisted vacuum thrombectomy (CAVT) met its predefined primary effectiveness and safety endpoints for the t ...

The ELEGANCE registry, which focuses on historically underrepresented populations to generate real-world evidence, evaluated en ...

Endovascular Engineering, Inc. (E2), a developer of technology for venous thromboembolism, announced FDA 510(k) clearance for b ...

A secondary analysis of the randomized SirPAD trial demonstrated lower rates of target-lesion revascularization (TLR) and major ...

One-year results from the prospective, multicenter, single-arm PROMISE III trial evaluated transcatheter arterialization of the ...

Six-month results from Esprit BTK PAS were reported in patients with chronic limb-threatening ischemia (CLTI) treated with the ...

A post hoc analysis of the randomized HI-PEITHO study examined potential predictors of major bleeding in patients with acute in ...